This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chuu, C.-p. Articles by Liao, S. Search for Related Content PubMed PubMed Citation Articles by Chuu, C.-p. Articles by Liao, S.

Androgen Causes Growth Suppression and Reversion of Androgen-Independent Prostate Cancer Xenografts to an Androgen-Stimulated Phenotype in Athymic Mice

¹ Ben May Institute for Cancer Research, Department of Biochemistry and Molecular Biology and ² Committee of Cancer Biology, University of Chicago, Chicago, Illinois

Requests for reprints: Shutsung Liao, Committee of Cancer Biology, University of Chicago, MC6027, 5841 South Maryland Avenue, Chicago, IL 60637. Phone: 773-702-6999; Fax: 773-834-1770; E-mail: sliao{at}uchicago.edu.

Most prostate cancer patients develop androgen-independent recurrent prostate tumors a few years after androgen ablation therapy. No therapy, however, has been shown to substantially extend survival in these patients. Previously, we reported that androgen suppresses the growth of androgen-independent LNCaP prostate tumor cells both in vitro and in vivo. In cell culture, androgen receptor (AR)–rich androgen-independent LNCaP 104-R1 cells adapt to growth suppression by androgen and then their growth is androgen stimulated. Because maintaining androgen dependency of prostate tumor cells should prolong the usefulness of androgen ablation therapy, we determined if androgen-independent prostate tumors would revert to an androgen-stimulated phenotype in vivo upon androgen treatment. Growth of the LNCaP 104-R1 tumors was suppressed by androgen, but tumors then adapted to suppression by androgen and growth became androgen stimulated. Tumor AR and prostate-specific antigen mRNA and protein were initially high in 104-R1 tumors but decreased during adaptation. Subsequent removal of androgen decreased the serum prostate-specific antigen level further and stopped the growth of the adapted tumors. Because androgen caused growth suppression and then reversion of androgen-independent tumors to an androgen-stimulated phenotype and because the growth of androgen-stimulated tumors could be restrained by androgen ablation, these results suggest a novel therapy for AR-positive androgen-independent prostate cancer.

Key Words: LNCaP • prostate cancer progression • tumor growth suppression • androgen receptor • PSA

This article has been cited by other articles:

				P. Mathew Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial Ann. Onc., February 1, 2008; 19(2): 395 - 396. [Full Text] [PDF]

				M. V. Gavrielides, A. M. Gonzalez-Guerrico, N. A. Riobo, and M. G. Kazanietz Androgens Regulate Protein Kinase C{delta} Transcription and Modulate Its Apoptotic Function in Prostate Cancer Cells Cancer Res., December 15, 2006; 66(24): 11792 - 11801. [Abstract] [Full Text] [PDF]

				L. Peng, P. J. Malloy, J. Wang, and D. Feldman Growth Inhibitory Concentrations of Androgens Up-Regulate Insulin-Like Growth Factor Binding Protein-3 Expression via an Androgen Response Element in LNCaP Human Prostate Cancer Cells Endocrinology, October 1, 2006; 147(10): 4599 - 4607. [Abstract] [Full Text] [PDF]

				C.-p. Chuu, R. A. Hiipakka, J. M. Kokontis, J. Fukuchi, R.-Y. Chen, and S. Liao Inhibition of Tumor Growth and Progression of LNCaP Prostate Cancer Cells in Athymic Mice by Androgen and Liver X Receptor Agonist. Cancer Res., July 1, 2006; 66(13): 6482 - 6486. [Abstract] [Full Text] [PDF]

				Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang Androgen and its receptor promote bax-mediated apoptosis. Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916. [Abstract] [Full Text] [PDF]